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Introduction
Condition in which the cornea becomes thin
and loses tensile strength, and subsequently devel-
ops warpage and irregular astigmatism, are referred
to as corneal ectasias. Ectatic condition of the
cornea can cause very poor vision(1).
Keratoconus (KCN) is a progressive, non-
inflammatory ectacic disorder characterized by
bilateral and asymmetrical conical protrusion of the
cornea(2) with a reported frequency in the general
population of approximately 1 in 2000(3). It is
notable that keratoconus is a multifactorial disease
caused by several genes disorder, environmental
factors and ultrastructural alteration of the collagen
matrix(4). According to the keratoconus stage and its
progression, different treatments can be used. In the
early stages, spectacles or contact lenses can correct
this abnormality, whereas in advance cases because
of the progressive increase in myopia and corneal
irregularity, these optical means cannot resolve the
visual blur. Surgical treatments such as intrastromal
corneal ring segments (ICRS) and corneal collagen
cross-linking (CXL) with riboflavin and ultraviolet
A (UVA) can be used in higher stages as less inva-
sive procedures(5-7).
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ABSTRACT
Purpose: To compare combined MyoRing implantation with previously corneal collagen cross-linking (CXL- MyoRing) versus
MyoRing implantation alone in patients with keratoconus. 
Methods: This retrospective, comparative, cohort study included 33 eyes of 33 patients with keratoconus stage II and III
according to Amsler-Krumeich classification. Two groups were performed for this study with 1 year follow up. The group 1 received
MyoRing implantation and the group 2 received CXL approximately 12 months before MyoRing implantation. All patients had a com-
plete pre and post-operative examination including visual, refractive and keratometry examinations.
Results: In Group 1 at the end of follow up the mean UDVA and CDVA improved by 9 and 4 lines of logMAR. In Group 2 the
mean UDVA and CDVA improved by 8 and 2 lines of logMAR. There was not observed a statistically significant difference between
mean UDVA of two groups postoperatively (p = 0.142) whereas the mean CDVA in Group 2 was significantly better than mean
Group 1 at the end of follow up (p= 0.018). Spherical equivalent error and refractive astigmatism were significantly reduced in both
groups which no statistically significant differences was noted in these refractive parameters between two groups. The mean kerato-
metric values also were reduced in both groups at the end of follow up which no statistically significant difference was observed
between two groups.
Conclusion: Both MyoRing implantation alone and combined MyoRing implantation with previously CXL were safe and effec-
tive methods for moderate and severe keratoconus and resulted in similar clinical outcomes after one year follow up.
ExclusivelyMyoRing implantation alone demonstrated better outcome in mean CDVA.
Key words: Corneal Collagen Cross-linking, MyoRing, Keratoconus, Intracorneal Ring Segment implantation
ICRS have been used to correct ectatic corneal
disease in order to reduce the corneal steepening,
reduce the irregular astigmatism and improve the
visual acuity in patients with clear cornea and con-
tact lens intolerance(5, 8, 9).
The main advantages of ICRS are safety,
reversibility, stability, and the fact that surgical
process does not affect the central corneal visual
axis(10).
The development of a new surgical approach
(corneal intrastromal implantation system-CISIS),
consisting of a safe and easy to use high precession
microkeratome for the creation of the corneal pock-
ets (Pocket Maker Microkeratome, Dioptex GmbH,
Austria) and a new kind of full ring implant
(MyoRing, Dioptex GmbH, Austria) allows a safe
and effective treatment of Myopia, keratoconus and
post-LASIK keratoectasia(11-13).
Cross-linking of collagen refers to the ability
of collagen fibrils to form strong chemical bonds
with adjacent fibrils. By this hypothesis, induction
of cross-links in corneal tissue was tested in order
to increase the stiffness as a basis for a future con-
servative treatment of keratectasia(7). Corneal colla-
gen crosslinking (CXL) with riboflavin and ultravi-
olet A (UVA) is a new technique to strengthen
corneal tissue using riboflavin as a photosensitizer
and UVA to increase the formation of intrafibrillar
and interfibrillar covalent bonds by photosentize-
doxidation. This technique stabilizes biomechanics
of cornea(14). Studies on CXL have reported stability
in progression of the keratoconus, but with minimal
improvement in vision quality of patients(15, 16). For
this reason combined procedures such as intrastro-
mal corneal ring (ICR) implantation have been pro-
posed to maximize the results from CXL(17, 18).
Although the combination of MyoRing
implantation and CXL have been done before and
showed safe and effective treatment(19, 20). To the best
of our knowledge, this is the first studywhich isper-
formed to compare combined MyoRing implanta-
tion with previously corneal collagen crosslinking
(CXL- MyoRing) versus MyoRing implantation in
patients with moderate and severe keratoconus.
Patients and methods
This retrospective, comparative, non-random-
ized, cohort study included 33 eyes of 33 patients
with keratoconus stage II and III according to
Amsler-Krumeichkeratoconus classification. All
surgeries were performed by the same surgeon.
Inclusion criteria for MyoRing implantation
was keratoconus grade II and III, contact lens intol-
erance, corneal thickness at the thinnest point of at
least 350 µm and the exclusion criteria included
grade I and IV of keratoconus, hydrops, corneal
opacity, corneal dystrophy, sever atopy, previous
ocular disease or surgery, autoimmune or other sys-
temic disease and pregnancy.
Inclusion criteria in order to realize CXL treat-
ment was progressive keratoconus confirmed by an
increase in maximum curvature of at least 1.00 D in
the previous 6 months as assessed by corneal
topography, no slit lamp evidence of corneal scar-
ing and  corneal thickness of at least 400 µm. 
Patients were divided into two groups. The
group 1 included 22 eyes of 22 patients with no
progressive keratoconus in whom only MyoRing
implantation was performed. Second group includ-
ed 11 eyes of 11 patients with progressive kerato-
conus. In group 2 the patients received crosslinking
treatment (CXL) approximately one year before
MyoRing implantation at the same place.
In both groups MyoRing implantation were
performed between March 2013 and April 2014 for
all patients at Bina Eye Hospital, Tehran, Iran. The
follow up time after MyoRing implantation in both
groups was 12 months.
Inclusion criteria for MyoRing implantation
was keratoconus grade II and III, contact lens intol-
erance, corneal thickness at the thinnest point of at
least 350 µm and the exclusion criteria included
grade I and IV of keratoconus, hydrops, corneal
opacity, corneal dystrophy, sever atopy, previous
ocular disease or surgery, autoimmune or other sys-
temic disease and pregnancy.
Inclusion criteria in order to realize CXL
treatment was progressive keratoconus confirmed
by an increase in maximum curvature of at least
1.00 D in the previous 6 months as assessed by
corneal topography, no slit lamp evidence of
corneal scaring and  corneal thickness of at least
400 µm. 
All patients had a complete preoperative and
postoperative examination including manifest
refraction, corrected distance visual acuity (CDVA),
uncorrected distance visual acuity (UDVA) using a
standard Snellen chart, Goldman applana-
tiontonometry,pachymetry, corneal topography
(Orbscan II, Baush & Lomb), slit lamp microscopy
and fundus examination. Diagnosis of keratoconus
was established by the combination of computed
videokeratography for anterior and posterior
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corneal surface (Orbscan II; Baush&Lomb), ker-
atometry readings, and corneal pachymetry and slit
lamp findings.
Surgical technique
All operations were performed by the same
surgeon (KH.J). Corneal crosslinking was per-
formed with a UVA light and full ring intracorneal
implantation (MyoRing, Dioptex, GmbH) with
PocketMakerMicrokeratome.
Corneal collagen crosslinking (CXL)
The CXL procedure was performed in an
operating room under sterile conditions. Topical
anesthetic eye drops were applied. After manual
abrasion of the corneal epithelium of at least 7.0
mm, riboflavin 0.1% solution in 20% dextran was
applied to the cornea every 2 to 3 minutes during
30 minutes. Saturation ofthe cornea with riboflavin
and its presence in the anterior chamber were moni-
tored closely at the slit lamp before treatment
began. Ultraviolet-A (UVA) irradiation was per-
formed using an optical system (Koehler illumina-
tion) consisting of an array of 7 UVA diodes with a
potentiometer to allow regulation of voltage. Before
treatment, the intended surface irradiance of 3
mW/cm2 (5.4 J/cm2 surface dose) was calibrated
using a UVA meter (LaserMate-Q, Laser 2000) at a
working distance of 6 cm. Irradiance was per-
formed for 30 minutes using 3 mW/cm2, corre-
sponding to a surface dose of 5.4 J/cm2.
During treatment, riboflavin solution was
applied every 3 minutes to saturate the cornea with
riboflavin and moisten the cornea.After the treat-
ment, topical ciprofloxacin 0.3% (SinaDarou) was
applied and a bandage contact lens (Bausch &
Lomb PureVisionof material balafilcon A) fitted to
the corneal surface until re- epithelialization.
Bandage lens was removed within 3 to 5 days,
pending epithelial healing. Patients were given
betamethasone disodium phosphate drops 0.1 %,(
SinaDarou) 4 times daily, with gradual tapering
over the following 2 months.
MyoRing Implantation
The MyoRing implantation was performed in
an operating room under sterile conditions and topi-
cal anesthesia (Proparacaine hydrochloride 0.5%).
An operation microscope (OMS-800 standard TOP-
CON Corporation, Japan) was used to mark the
central point of intrastromal corneal ring.
Additionally, the appropriate MyoRing dimensions
were determined according to the
MyoRingnomogram which takes into account the
corneal thickness at its thinnest point and the aver-
age keratometry (K) - reading.
An intrastromal pocket of 9 mm in diameter
and 300 µm in depth was created via a small inci-
sion of 3 mm using the Pocket Maker
Microkeratome as described in detail elsewhere(11).
The Microkeratome has a suction ring and a motor-
driven blade. First, the suction ring fixes the
applanator to the cornea and then the micro-vibrat-
ing diamond creates the stromal pocket. Once the
pocket is created, the MyoRing is inserted into the
pocket using implantation forceps and centration is
adjusted using a keratoscope. All procedures were
performed with the temporal approach of self-seal-
ing incisions. No intraoperative complications were
noted during the surgical procedure in any case.
Postoperatively, a silicone bandage contact lens was
placed on the cornea and removed 24 hours after
the operation. Postoperative treatment included a
combination of betamethasone drops (SinaDarou),
chloramphenicol drops (SinaDarou), and non-pre-
served artificial tear (Artelac; Baush& Lomb) 4
times daily. Chloramphenicol was discontinued 1
week postoperatively whereas betamethasone was
tapered during 4-6 weeks. 
Statistical analysis 
Statistical analysis was performed using SPSS
for windows (version 21; SPSS Inc., Chicago, IL,
USA). All visual acuity measurements were con-
verted from Snellen notation to logMAR. The nor-
mality of data was checked using Kolmogorov-
Smirnov (K-S) test. Continuous variables are
expressed as mean ± SD.The statistical significance
of the differences in mean levels of normally dis-
tributed variables between pre cxl and post cxl was
examined using the paired t-test. A one-way repeat-
ed measures ANOVA was conducted to compare
the effect of surgery groups; Group1 (MyoRing
implantation) and group 2 (CXL+ MyoRing) on
UDVA, CDVA,SE,Sphere, Cylinder, Max K, Min
K, and Mean K before and after MyoRing implan-
tation. The threshold of statistical significance was
a p value less than 0.05.
Results
Group 1 included 22 eyes of 22 patients, 18
men (81.8%) and 4 women (18.2%), with a mean
age of 24.63 ± 3.06 (SD) (range 18 to 28 years)
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who had only MyoRing implantation. Of these eyes
15 eyes (68.1 %) and 7 eyes (31.8 %) had stage II
keratoconus and stage III keratoconus, respectively.
The mean time of follow-up was 12 month.Patients
in group 2 received CXL treatment before MyoRing
implantation. The mean interval time between CXL
and MyoRing implantation was 12 months. This
group included 11 eyes of 11 patients, 8 men (72.7
%) and 3 women (27.3 %), with a mean age of
20.40 ± 3.58 (SD) (range 17 to 27 years). There
were 7 eyes (63.6%) with stage II keratoconus and
4 eyes (36.3%) with stage III keratoconus (table 1).
In group 2, there was no significant difference
in mean UDVA, CDVA, SE, sphere and manifest
cylinder before and after CXL treatment, whereas
there was a statistically significant increase in ker-
atometric values after CXL treatment (p<0.001)
(table 2).
Table 3 demonstrates that there is no differ-
ence between 2 groups over the time for all vari-
ables except for CDVA. Additionally, it shows that
in group 1 the mean UDVA was improved by 9
lines of logMAR (p< 0.001) and the mean CDVA
was improved approximately by 4 lines of logMAR
(p< 0.001).In group 1 the amount of reduction for
SE, sphere and cylinder of manifest refraction were
6.08, 4.67 and 3.37 D at 12 months postoperatively,
respectively (p< 0.001). Also, the maximum k value
(K max), minimum k value (k min) and average k-
value (k mean) were decreased approximately by
5.54, 2.24 and 4.00 D at 12 months postoperatively,
respectively (p< 0.001). In group 2, comparing the
results after CXL treatment versus post CXL +
MyoRing implantation showed a significant differ-
ence in all parameters. The mean UDVA improved
from 1.08 ± 0.30 to 0.34 ± 0.20 (approximately 8
lines of log MAR) after MyoRing implantation
(p<0.001). The mean CDVA improved from 0.44 ±
0.14
t o
0.22
±
0.14
(approximately 2 lines of log MAR) after MyoRing
implantation (p =0.002). In this group, the mean
preoperative (post CXL) SE, sphere and cylinder of
manifest refraction decreased by 6.40, 5.18 and
2.54 D at the end of follow up respectively and the
maximum k value (K max), minimum k value (k
min ) and average k- value(k mean) decreased
approximately by 6.75, 2.96 and 4.85 D at 12
months postoperatively, respectively.
Discussion
MyoRing implantation and Corneal Collagen
Cross Linking (CXL) are two independent treat-
ment methods for treating Keratoconus.
MyoRing implantation is the technique of
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Variables Group 1N 22
Group 2
N 11 P value
Age 24.63 ± 3.06 20.40 ± 3.50 0.001
Sex 
Male 18 (81.8 %) 8 (72.7 %) 0.547
Female 4 (18.12 %) 3 (27.3 %)
KCN stage
Stage II 15 (68.1 %) 7 (63.6 %) 1
Stage III 7 (31.8 %) 4 (36.3 %)
Table 1: Demographic factors of study population.
Group 1, MyoRing implantation; Group 2 CXL+ MyoRing
implantation; KCN, keratoconus
Parameter Pre CXL Post CXL P value
UDVA (logMAR)
Mean ± SD 1.15 ± 0.27 1.08 ± 0.30 0.933
Range 0.50 to 1.60 0.70 to 1.60
CDVA (logMAR)
Mean ± SD 0.42 ± 0.10 0.44 ± 0.14 0.729
Range 0.30 to 0.60 0.30 to 0.60
SE (D)
Mean ± SD -8.53 ± 3.41 -9.00 ± 4.27 0.150
Range -15.00 to -4.00 -16.00 to -3.00
Sphere (D)
Mean ± SD -5.70 ± 3.69 -6.86 ± 3.95 0.091
Range -12.00 to -1.00 -14.00 to 0.00
Cylinder (D)
Mean ± SD -5.65 ± 1.29 -4.97 ± 1.38 0.116
Range -7.00 to -2.00 -7.00 to -2.50
Max K (D)
Mean ± SD 54.52 ± 5.45 55.09 ± 5.33 0.034
Range 45.00 to 61.00 45.20 to 60.16
Min K (D)
Mean ± SD 47.75 ± 3.71 48.51 ± 4.12 0.01
Range 42.00 to 53.40 43.40 to 55.00
Mean K( D)
Mean ± SD 51.14 ± 4.38 51.80 ± 4.50 0.03
Range 44.00 to 57.00 44.60 to 57.70
Table 2: Comparison of Pre CXL and post CXL outco-
mes in group 2.
UDVA = uncorrected distance visual acuity; CDVA = correc-
ted distance visual acuity; SE= spherical equivalent; K =
Keratometry; Max K = maximum K value; min K= minimum K
value; Mean K = average K value; D = diopter.
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Parameter Pre- op Post- op P Trend P Interaction
UDVA (log MAR)
Group 1
Mean ± SD 1.15± 0.27 0.22 ± 0.07
<0.001
0.120
Range 0.50 to 1.60 0.10 to 0.30
Group 2
Mean ± SD 1.08 ± 0.30 0.34 ± 0.20
<0.001
Range 0.70 to 1.60 0.00 to 0.60
CDVA (log MAR)
Group 1
Mean ± SD 0.53 ± 0.20 0.15 ± 0.05
<0.001
0.034
Range 0.30 to 1.00 0.10 to 0.20
Group 2
Mean ± SD 0.44 ± 0.14 0.22 ± 0.14
0.002
Range 0.30 to 0.60 0.00 to 0.40
SE(D)
Group 1
Mean ± SD -6.35 ± 3.21 -0.27±0.76
<0.001
0.785
Range -13.00 to -1.50 -1.50 to +1.00
Group 2
Mean ± SD -9.30 ± 4.27 -2.89 ± 2.48
<0.001
Range -16.00 to -3.00 7.50 to 0.50
Sphere(D)
Group 1
Mean ± SD -4.11 ± 3.17 0.56 ± 0.64
<0.001
0.707
Range -10.00 to 0.00 -0.75 to +1.00
Group 2
Mean ± SD -6.86 ± 3.95 -1.68 ± 2.35
0.002
Range -14.00 to 0.00 -6.00 to 1.00
Cylinder(D)
Group 1 Mean ± SD -5.00 ± 1.07 -1.63 ± 0.76
<0.001
0.094
Range -6.50 to -3.25 -3.50 to -0.50
Group 2 Mean ± SD -4.97 ± 1.38 -2.43 ± 0.80
<0.001
Range -7.00 to -2.50 -4.00 to -1.50
Max K(D)
Group 1
Mean ± SD 52.85 ± 3.09 47.31 ± 1.97
<0.001
0.148
Range 48.00 to 58.00 44 to 51.80
Group 2
Mean ± SD 55.09 ± 5.33 48.34 ± 3.01
<0.001
Range 45.20 to 60 .16 43.40 to 53.80
Min K(D)
Group 1
Mean ± SD 47.32 ± 3.09 45.08 ± 2.47
<0.001
0.336
Range 42.60 to 53.60 41.00 to 49.60
Group 2
Mean ± SD 48.51 ± 4.12 45.55 ± 2.81
0.007
Range 43.40 to 55.00 41.10 to 50.20
Mean K(D)
Group 1
Mean ± SD 50.13 ± 2.70 46.14 ± 2.53
<0.001
0.533
Range 46.20 to 55.60 42.50 to 49.50
Group 2
Mean ± SD 51.80 ± 4.50 46.95 ± 2.88
<0.001
Range 44.60 to 57.70 42.25 to 52.00
Table 3: Results of repeated measures analysis of variance for comparing means for visual and refractive outcomes in
two groups of Myoring and CXL + MyoRing implantation.
UDVA, uncorrected distance visual acuity; CDVA, corrected distance visual acuity; SE, spherical equivalent K, keratometry; Max K,
maximum k value; Min K, minimum K value; Mean K, average K value; D, diopter; Group 1: MyoRing implantation; Group 2: CXL
+ MyoRing implantation; Pre- op: beforMayoRing implantation; Post- op: after MayoRing implantation  
installing the complete intrastromal ring in the
developed pocket in cornea. The mechanism of this
technique involves adding a volume to the periph-
ery which leads to a new biomechanical equilibri-
um of the cornea, thereby flattening its center(11, 12).
It has been demonstrated that the treatment of kera-
toconus, post-LASIK ectasiaand pellucid marginal
degeneration withMyoRing implantation is effec-
tive, minimally invasive, and easy to perform(21-25).
The primary indication for the use of CXL is
to inhibit the progression of corneal ectasia such as
keratoconus(26-29). Healthy cornea contains crosslinks
between collagen fibers by which it stays in normal
shape. These links are reduced in Keratoconus
which in turn results in a bulge with outward orien-
tation. In CXL these crosslinks are reproduced to
help cornea regain its standard conditions(7, 14, 15). The
present study evaluates the effectiveness of
MyoRing implantation independently and MyoRing
implantation with previously operated patients
using CXL for the first time in   patients with
Keratoconus.
The results of current study indicated the
effectiveness of independent MyoRing implanta-
tion. This method reduced spherical and cylindrical
component of manifest refraction as well as kerato-
metric values. The mean UDVA and CDVA
improved significantly after the independent
implantation of MyoRing. Other studies on
MyoRing implantation demonstrated the similar
results(21-25). Jabbarvand et al.(23) evaluated a sample
of 98 eyes of 98 patients who underwent MyoRing
implantation through whichthe mean UDVA and
CDVA after one year follow up improved by 6 and
3 lines of logMAR, meanwhile, in the current study
in group who had only MyoRing implantation ,the
mean UDVA and CDVA improved by 9 and 4 lines
of logMAR, respectively. Jabbarvand’s results for
refractive parameters such as sphere, cylinder and
SE illustrated 5.50, 3.00 and 7.00 D changes
respectively. In accordance to jabbarvand study,
these changes were 4.67, 3.37 and 6.08 D in our
study. They suggested that this treatment approach
is a successful method for Keratoconus treatment. 
It has been shown that MyoRing implantation
leads to visual rehabilitation in keratoconic patients
and it also can stop the progression of the disease
by creating a new biomechanical equilibrium(30).
Studies on Keratoconus patients reported vari-
ous results regarding the effectiveness of CXL(27-29, 31,
32). Raiskup-Wolf et al.(28) reported the effectiveness
of CXL for keratoconus treatment in a 6- year fol-
low up. Their results showed a significant improve-
ment in CDVA (1 line logMAR). Also according to
their results the maximum k value decreased by
1.46 D(28). However, in current study after CXL
treatment, maximum k value increased by 0.57 D
and we did not observed a significant improvement
in mean CDVA, following CXL treatment.
Wollensak et al.(29) reported that in order to observe
the positive outcomes of CXL, a long follow up
period is required which was in consistence with
some studies(27, 32). Agrawal et al.(31) investigated the
effect of CXL treatment in 41 Indian patients with
progressive keratoconous after 12 months follow-
up. Their results showed at least 1 line improve-
ment in CDVA and the maximum keratometry
value decreased by 2.47 D. However the results of
this study demonstrated that there is no change in
visual and refractive outcomes (UDVA, CDVA, SE,
sphere and cylinder of manifest refraction) but a
slight increase in keratometric values after CXL.
In a systematic review realized by
TianChunyu et al.(33) of 3 studies with 84 partici-
pants, a small regression of corneal topography was
found after 18 months post- CXL; K mean value
was not significantly different at 18 months post
CXL. Likewise based on the result of 5 studies that
included 181 participants, the mean UDVA was not
improved, only CDVA still showed significant
improvement after 18 months post CXL. Our
results after CXL procedure were in accordance to
these studies which had 18 months follow up.
However, one must not forget that CXL treat-
ment likely only stops or slows down, rather than
prevent the progression of keratoconus. A small
regression that occurred in our study after CXL
treatment may be explained as an effect of the
rearrangement of corneal lamellae and the sur-
rounding matrix(34, 35).
Considering the collagen turnover in the
cornea over several years, long term studies have
yet to determine whether repeated CXL treatment is
necessary. Currently no studies have assessed
repeated CXL procedures in keratoconus patients
because some authors believe that CXL yield good
results in long term follow up(27, 29, 32).
While CXL has been shown to halt kerato-
conus progression, its effect on visual rehabilitation
may be insufficient. Intarcorneal ring segments
(ICRS) produce rapid and substantial improvement
in visual parameters but do not halt keratoconus
progression(36).
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Therefore a logical solution would be to com-
bine the two treatment methods in order to syner-
gize their effect. This way the CXL procedure could
be done first in order to stabilize the cornea, fol-
lowed by ICRS implantation in order to flattening
and regularizing the cornea.
Previous studies on ICRS demonstrated the
effectiveness of these two treatment together for
keratoconus(17, 18, 37), also the combination of full ring
implantation (MyoRing) and CXL, can lead to
improvement and a long term stability of visual
acuity in patients with keratoconus(12). However
none of these previous studies evaluated the effect
of MyoRing implantation with previously CXL
treatment in patients who suffered progressive kera-
toconus.
The data from examining group who received
both treatments (CXL and MyoRing implantation)
demonstrated that changes in visual, refractive and
keratometry outcomes after MyoRing implantation
in comparison with post CXL were statistically sig-
nificant. The improvement in mean UDVA and
CDVA after MyoRing implantation in the group
who had CXL prior to MayoRing implantation
were approximately 8 and 2 lines of logMAR. It
seems that MyoRing implantation is more benefi-
cial than CXL for improving visual and refractive
outcomes. MyoRing implantation significantly flat-
tens and regularizes the cornea(21-25).
Coskunseven et al.(17) evaluated the effect of
combined KeraRing implantation and CXL when
applied in two groups with different order of using
each method.The study included 48 eyes of 43
patients with keratoconus (Group 1: ICRS first then
CXL; Group 2: CXL first then ICRS; mean interval
between treatments was approximately 7 months).
They evaluated several parameters such as UDVA,
CDVA, SE, Cylinder, and Kmean. Their results
demonstrated that incorporation of these methods
could provide better outcomes, especially when
CXL is applied after ICRS implantation. In
Coskunseven et al.(17) study the group 2 which CXL
was applied before ICRS implantation showed
approximately 1 line improvement in UDVA and
CDVA. The SE and cylinder of manifest refraction
decreased by 4.15 and 1.76 D, respectively(38).
In accordance with Coskunseven study,
notably the current study showed a greater
improvement for CDVA (approximately 2 lines)
and UDVA (approximately 8 lines) in group who
had CXL treatment prior to MyoRing implantation.
It is notable that Kmean reduction on their study
was 4.16 D, whereas in current study was observed
a greater reduction (4.85 D).
Chan et al.(37) in a retrospective comparative
study analyzed 12 eyes of 9 patients who had Intacs
implantation without CXL and 13 eyes of 12
patients who had Intacs implantation followed by
CXL. The combined surgery group had a signifi-
cantly greater reduction in cylinder (2.73 versus
1.48 D) and the maximum k value (1.94 versus 0.89
D) than the group having Intacs implantation only.
In spite of the study conducted by Chan et al, the
current study showed almost no significant differ-
ences between parameters of two groups. 
A prospective study conducted by Renesto et
al. after a 2- year follow up period (39 eyes)
showed no difference between patients treated with
ICRS implantation alone and patients treated with
CXL followed by ICRS implantation 3 months
later. Both groups showed similar results in terms
of refractive, topographic and paquimetric parame-
ters(39).
A similar retrospective comparative study per-
formed by Legareet al. on 66 eyes showed that 1
year postoperatively, the 34 eyes treated with ICRS
had better visual and keratometric results than the
32 eyes treated with a combination of CXL and
ICRS(40).
In agreement with Renesto et al. and Legareet
al. studies, in current study no significant differ-
ences were observed in association with UDVA,
SE, sphere, cylinder and keratometric values
between two groups (table 2). Only the mean
CDVA had a greater improvement (approximately 2
lines of logMAR) in group who had MyoRing
implantation alone.
Studeny et al.(20) described the use of combined
MyoRing implantation and CXL in one session in a
group of patients with keratoconus. The study
included 22 eyes of 22 patients. After 12 months
follow up the mean UDVA improved by 6 lines and
the mean CDVA improved approximately by 2.50
lines. Our results in group who had CXL approxi-
mately 12 months prior to MyoRing implantation
were in accordance with Studeny et al. study, how-
ever we have a greater improvement in mean
UDVA.
Also, the mean sphere and cylinder reduced by
2.76 and 1.61 D, respectively in Studeny et al.
study, whereas in current study sphere and cylinder
decreased by 5.18 and 2.54 D in group with both
treatment. As it can be seen we obtained more satis-
factory results in comparison with Studeny et al.
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study. Comparing our results to Studeny et al. study
leads us to the following hypothesis that more
favorable outcomes will be obtained if we apply
CXL treatment prior to MyoRing implantation
instead of realize combined treatment in one ses-
sion, because a slight improvement in long term
follow up period is a common finding.
Moreover, our results in both groups especial-
ly in group who had CXL before MyoRing implan-
tation raise a question if MyoRing can stop the pro-
gression of keratoconus?
It has been demonstrated that the progression
of keratoconus seems to be associated with selec-
tive proteolytic activity which alters the regular
orthogonal matrix pattern of the corneal lamellae(41),
in the other word the progression of keratoconus is
the result of the biomechanical weakness of the dis-
eased cornea. The current study in agreement with
previous studies on MyoRing implantation suggests
that MyoRing implantation alone may have suffi-
cient power to stop progression of keratoconus
without CXL treatment. 
Generally, there are two possibilities to
strengthen the cornea in order to stop progres-
sion:1st Hardening the corneal tissue on an ultra-
structural level by means of corneal collagen
crosslinking, 2 ndTo support the cornea by adequate
mechanical means without changing the itself tis-
sue. Such a support could be the MyoRing implan-
tation. Since MyoRing is a closed, complete ring
and located in a pocket that is larger the diameter of
the implant and not captured in a tunnel like ICRS,
the cornea can find a new biomechanical equilibri-
um around the implant and resting biomechanically
neutral in the postoperative corneal shape(42).
However further studies with longer follow up peri-
ods are required to clarify this issue in more details.  
Although there was no complication in any
case during and after surgery, this study had some
limitation including the short follow up period,
limited number of patients in each group; thus it
would be interesting to carry out further long term,
prospective study with more participant to evaluate
the effect of combined CXL treatment and
MyoRing implantation. 
Finally we could conclude that MyoRing
implantation alone versus MyoRing implantation
with previously CXL treatment were both safe and
effective methods for moderate and sever kerato-
conus. Also the group with  MyoRing implantation
demonstrated more improvement in mean CDVA at
the end of follow up and both groups had the  same
effect on visual, refractive and keratometricout-
comes.It seems that CXL treatment needs longer
follow up to show better results and the biomechan-
ical effect of CXL would be present in more longer
postoperative period. We also assume that MyoRing
implantation could be stop or slow down the pro-
gression of keratoconus, however to confirm these
findings it is fundamental  accomplish further
prospective comparative study with longer follow
up time for both methods of treatment.
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